Navigation Links
Rochester Medical Reports Third Quarter Results
Date:7/26/2012

oking statements" with the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about the future financial and operating results of Rochester Medical.  Such statements are based on currently available information, operating plans and management's expectations about future events and trends.  Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, and  our level of success in increasing  Rochester Medical Direct Sales revenue, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of Private Label Sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2011, and quarterly reports on Forms 10-Q.  Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made.  The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial MeasuresRochester Medical has provided Non-GAAP Net Income in addition to net income calculated in accordance with generally accepted accounting princ
'/>"/>

SOURCE Rochester Medical Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
2. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
3. Plainfield Precision Achieves ISO 13485:2003 Quality Management Certification for Medical Device Manufacturing
4. Medbox, Inc. To Support Referendum Overturning LA City Council Ban on Medical Marijuana Outlets
5. Global Cables and Leads for Medical Equipment Industry
6. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
7. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2012
8. PhytoSPHERE Systems, a Medical Marijuana Inc Portfolio Company, to Bring Production Facilities to Europe through Canipa Holdings.
9. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
10. Winner Medical Enters into Definitive Merger Agreement with Winner Holding Limited
11. No Medical Degree Necessary: An Easy Guide to Understanding Your Probiotic Supplement Label
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Amgen (NASDAQ: ... quarter of 2014. Key results include: , Total ... percent product sales growth driven by strong performance across ... (carfilzomib), Prolia ® (denosumab) and XGEVA ® ... to $2.37, driven by higher revenues and a significant ...
(Date:7/29/2014)... 2014 Pfenex Inc. (NYSE MKT: PFNX) today announced ... of 8,333,333 shares of its common  stock at a price ... common stock was offered by Pfenex. In addition, Pfenex has ... 1,250,000 additional shares of common stock at the initial public ... the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... 29, 2014 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today reported net income for the ... per diluted share, and non-GAAP net income of $94.0 million, ... period a year earlier was $93.3 million, or $0.81 per ... $0.84 per diluted share.  Net sales for ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Pfenex Announces Closing of Initial Public Offering 2Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11
... THE WOODLANDS, Texas , Aug. 3 ... LXRX ), a biopharmaceutical company focused on discovering breakthrough treatments ... second quarter 2010 financial results on Monday, August 9, ... hold a conference call to discuss its clinical development progress ...
... Aug. 3 Excaliard Pharmaceuticals, Inc., today announced positive ... new chemical entity for reducing fibrosis.  Results showed that EXC 001 ... compared to placebo.   , ... In the randomized, double-blind multicenter study ...
Cached Medicine Technology:Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results 2Excaliard Announces Positive Data From Phase 2 Clinical Trial of Its Anti-Scarring Drug, EXC 001 2
(Date:7/29/2014)... For survivors of severe combat injuries threatening more than ... a good record of safety and effectiveness in avoiding ... Plastic and Reconstructive Surgery , the ... Plastic Surgeons (ASPS). , Experience with multiple limb ... shows good success rates, with no increase in complications ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Chlorine helps keep ... more likely to develop eye infections, doctors say. ... as well as blurry vision, said Dr. Sampson Davis, ... in New Jersey. It,s important to understand why ... washes away the outer film layer of the eye ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 According to ... of Time Magazine titled “From Kim’s Butt to Angelina’s ... Kardashian’s butt is the celebrity feature most requested ... features include Beyoncé’s butt, Jennifer Lawrence’s nose, ... information is based on data collected by an online ...
(Date:7/29/2014)... Hudson County, NJ (PRWEB) July 29, 2014 ... that two leading pediatricians have joined our network, ... Regina Politis and Dr. Sushma Kaki. Hundreds of ... Medical Group, a comprehensive network of top doctors ... range of specialties. This latest acquisition represents CarePoint ...
(Date:7/29/2014)... D.C. (PRWEB) July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. , The ...
Breaking Medicine News(10 mins):Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... NEW YORK, Dec. 6 Informed Medical Communications ... the,bio-pharmaceutical industry, today announced the sale of its ... WA, HealthTalk is a,leading online source of chronic ... audience among patients and caregivers. The,announcement was made ...
... EDITOR,S PICK: Anticancer drugs might be of benefit to ... an inherited blood disorder caused by a genetic mutation ... of the beta-globin chain of hemoglobin (Hb). Red blood ... shape upon deoxygenation and this causes them to get ...
... Videos Created by Hospitals from Around the Country Appeal to the ... First-Ever Contest to Win a Free MRI, MALVERN, Pa., Dec. ... their community, but can,t seem to find the time,now,s your chance ... just,one click of your mouse! The video posting period in Siemens ...
... Dec. 6 /PRNewswire-FirstCall/ - Neurochem,(International) Limited (Neurochem), a ... TSX: NRM), announces that the Company has received ... Administration (FDA),that Neurochem,s response to the July 2007 ... eprodisate (KIACTA(TM)) for the treatment of,Amyloid A (AA) ...
... Today, the American,Medical Women,s Association (AMWA) announced that ... discuss his plan for health care reform,with thousands ... the,country on December 7., "As women and ... issue of health care is to our country ...
... by St. Jude Childrens Research Hospital scientists offers new ... excess proteins and could lead to new cancer treatments. ... carry out protein disposal, a finding that helps to ... this process. The discovery is important because the newly ...
Cached Medicine News:Health News:Informed Medical Communications Sells Consumer Internet Division to Revolution Health 2Health News:JCI online early table of contents: Dec. 6, 2007 2Health News:JCI online early table of contents: Dec. 6, 2007 3Health News:JCI online early table of contents: Dec. 6, 2007 4Health News:JCI online early table of contents: Dec. 6, 2007 5Health News:JCI online early table of contents: Dec. 6, 2007 6Health News:JCI online early table of contents: Dec. 6, 2007 7Health News:JCI online early table of contents: Dec. 6, 2007 8Health News:JCI online early table of contents: Dec. 6, 2007 9Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 2Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 3Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 2Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 3Health News:AMWA Hosts Health Care Conversation With Congressman Kucinich 2Health News:St. Jude finds mechanism for faulty protein disposal 2Health News:St. Jude finds mechanism for faulty protein disposal 3Health News:St. Jude finds mechanism for faulty protein disposal 4
... features of the Mastercycler ep Extremely ... blocks with SteadySlope technology Intuitive graphic ... device, a Mini-Satellite system, or a PC-controlled ... (Electronic Sample Protection) Optional motorized lid for ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
... Thermo Electron's most advanced personal gradient option ... use sophisticated onboard software and a large ... offer performance, accuracy and simplicity in thermal ... customer driven features built up on years ...
Medicine Products: